Published in Science on March 09, 1990
Gene Transfer for HIV Using Autologous T Cells (Gene Transfer) | NCT01153646
Configurationally defined phosphorothioate-containing oligoribonucleotides in the study of the mechanism of cleavage of hammerhead ribozymes. Nucleic Acids Res (1991) 2.72
Human immunodeficiency virus vectors for inducible expression of foreign genes. J Virol (1992) 2.70
Genetic therapies against HIV. Nat Biotechnol (2007) 2.50
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med (2009) 2.21
Artificial regulation of gene expression in Escherichia coli by RNase P. Proc Natl Acad Sci U S A (1995) 2.14
Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nat Nanotechnol (2011) 2.09
A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1993) 2.05
Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc Natl Acad Sci U S A (1992) 1.96
The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA (1997) 1.84
Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1. EMBO J (1994) 1.77
Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression. J Virol (1992) 1.68
RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy. J Nanosci Nanotechnol (2005) 1.68
Prevention of human immunodeficiency virus type 1 integrase expression in Escherichia coli by a ribozyme. Proc Natl Acad Sci U S A (1991) 1.64
Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci U S A (1997) 1.53
Minimal sequence requirements for ribozyme activity. Proc Natl Acad Sci U S A (1992) 1.50
Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev (1995) 1.49
Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator. Proc Natl Acad Sci U S A (1992) 1.45
Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages. Nucleic Acids Res (1993) 1.44
Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc Natl Acad Sci U S A (2000) 1.40
Can hammerhead ribozymes be efficient tools to inactivate gene function? Nucleic Acids Res (1994) 1.39
Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers. Nano Today (2012) 1.39
Electronic detection of nucleic acids: a versatile platform for molecular diagnostics. J Mol Diagn (2001) 1.38
Nuclease resistant ribozymes with high catalytic activity. EMBO J (1992) 1.38
Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci U S A (1991) 1.37
Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. J Virol (1993) 1.36
Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Mol Cell Biol (1995) 1.35
Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev (2010) 1.32
Expression of a chimeric ribozyme gene results in endonucleolytic cleavage of target mRNA and a concomitant reduction of gene expression in vivo. EMBO J (1992) 1.31
Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc Natl Acad Sci U S A (1996) 1.30
Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA. J Virol (1991) 1.29
A circular trans-acting hepatitis delta virus ribozyme. Nucleic Acids Res (1993) 1.27
A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc Natl Acad Sci U S A (1996) 1.27
RNA enzyme-directed gene therapy. Proc Natl Acad Sci U S A (1993) 1.25
Fabrication of 14 different RNA nanoparticles for specific tumor targeting without accumulation in normal organs. RNA (2013) 1.24
Fabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging. ACS Nano (2010) 1.21
Cytoplasmic delivery of ribozymes leads to efficient reduction in alpha-lactalbumin mRNA levels in C127I mouse cells. EMBO J (1992) 1.21
A small nucleolar RNA:ribozyme hybrid cleaves a nucleolar RNA target in vivo with near-perfect efficiency. Proc Natl Acad Sci U S A (1999) 1.20
Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology. Nucleic Acid Ther (2012) 1.19
Importance of independence in ribozyme reactions: kinetic behavior of trimmed and of simply connected multiple ribozymes with potential activity against human immunodeficiency virus. Proc Natl Acad Sci U S A (1993) 1.19
RNA aptamers directed to human immunodeficiency virus type 1 Gag polyprotein bind to the matrix and nucleocapsid domains and inhibit virus production. J Virol (2010) 1.18
Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci U S A (1998) 1.17
Development of HIV vectors for anti-HIV gene therapy. Proc Natl Acad Sci U S A (1996) 1.15
Extensive phosphorothioate substitution yields highly active and nuclease-resistant hairpin ribozymes. Nucleic Acids Res (1992) 1.15
Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells. Proc Natl Acad Sci U S A (1994) 1.12
Novel mechanism of hexamer ring assembly in protein/RNA interactions revealed by single molecule imaging. Nucleic Acids Res (2008) 1.12
Fabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cells. Nat Protoc (2013) 1.11
Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res (1992) 1.09
Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1. Nucleic Acids Res (1993) 1.08
Identification of cellular cofactors for human immunodeficiency virus replication via a ribozyme-based genomics approach. J Virol (2004) 1.08
Novel cell and gene therapies for HIV. Cold Spring Harb Perspect Med (2012) 1.07
Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. Gene Regul Syst Bio (2008) 1.05
Complete inhibition of virion assembly in vivo with mutant procapsid RNA essential for phage phi 29 DNA packaging. J Virol (1996) 1.04
Construction of a novel RNA-transcript-trimming plasmid which can be used both in vitro in place of run-off and (G)-free transcriptions and in vivo as multi-sequences transcription vectors. Nucleic Acids Res (1991) 1.03
Assembly of multifunctional phi29 pRNA nanoparticles for specific delivery of siRNA and other therapeutics to targeted cells. Methods (2011) 1.03
Ribozymes which cleave arenavirus RNAs: identification of susceptible target sites and inhibition by target site secondary structure. J Virol (1992) 1.03
Tat- and Rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1: a temporal analysis. J Virol (1992) 1.02
Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III. J Virol (1999) 1.02
Antigenomic Hepatitis delta virus ribozymes self-cleave in 18 M formamide. Nucleic Acids Res (1991) 1.02
A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. J Virol (1996) 1.02
Ribozyme cleaves rex/tax mRNA and inhibits bovine leukemia virus expression. Proc Natl Acad Sci U S A (1993) 1.02
Newt satellite 2 transcripts self-cleave by using an extended hammerhead structure. Mol Cell Biol (1991) 1.01
Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs. Proc Natl Acad Sci U S A (1995) 1.00
Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proc Natl Acad Sci U S A (1994) 0.99
Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA. Nucleic Acids Res (1995) 0.99
Design and specificity of hammerhead ribozymes against calretinin mRNA. Nucleic Acids Res (1993) 0.99
A ribozyme with DNA in the hybridising arms displays enhanced cleavage ability. Nucleic Acids Res (1992) 0.99
Enhancement of ribozyme catalytic activity by a contiguous oligodeoxynucleotide (facilitator) and by 2'-O-methylation. Nucleic Acids Res (1992) 0.98
Blockade of human immunodeficiency virus type 1 production in CD4+ T cells by an intracellular CD4 expressed under control of the viral long terminal repeat. Proc Natl Acad Sci U S A (1993) 0.98
Significantly higher activity of a cytoplasmic hammerhead ribozyme than a corresponding nuclear counterpart: engineered tRNAs with an extended 3' end can be exported efficiently and specifically to the cytoplasm in mammalian cells. Nucleic Acids Res (2001) 0.97
Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc Natl Acad Sci U S A (1994) 0.97
Assembly of therapeutic pRNA-siRNA nanoparticles using bipartite approach. Mol Ther (2011) 0.95
Determination of interactions between structured nucleic acids by fluorescence resonance energy transfer (FRET): selection of target sites for functional nucleic acids. Nucleic Acids Res (1998) 0.95
Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes. J Virol (1995) 0.95
Binding of intracellular anti-Rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: variations in viral inhibition. J Virol (1996) 0.95
Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA. Nucleic Acids Res (1997) 0.94
Stem cell-based anti-HIV gene therapy. Virology (2011) 0.94
The effect of structure in a long target RNA on ribozyme cleavage efficiency. Nucleic Acids Res (1997) 0.93
Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type I replication in permissive cell lines. Proc Natl Acad Sci U S A (1994) 0.93
Reduced beta 2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme. Nucleic Acids Res (1994) 0.92
Entropy-driven one-step formation of Phi29 pRNA 3WJ from three RNA fragments. Biochemistry (2014) 0.91
Gene therapy for infectious diseases. Clin Microbiol Rev (1998) 0.91
A ribozyme-mediated, gene "knockdown" strategy for the identification of gene function in zebrafish. Proc Natl Acad Sci U S A (1997) 0.89
Effective inhibition of herpes simplex virus 1 gene expression and growth by engineered RNase P ribozyme. Nucleic Acids Res (2001) 0.89
Engineered RNase P ribozymes effectively inhibit human cytomegalovirus gene expression and replication. Viruses (2014) 0.87
Inhibition of gene expression in human cells using RNase P-derived ribozymes and external guide sequences. Biochim Biophys Acta (2007) 0.87
Fluorogenic RNA nanoparticles for monitoring RNA folding and degradation in real time in living cells. Nucleic Acid Ther (2012) 0.87
Activation of HIV-specific ribozyme activity by self-cleavage. Nucleic Acids Res (1993) 0.87
Discrimination of a single base change in a ribozyme using the gene for dihydrofolate reductase as a selective marker in Escherichia coli. Proc Natl Acad Sci U S A (1997) 0.86
Ribozyme-mediated RNA degradation in nuclei suspension. Nucleic Acids Res (1995) 0.86
Engineered external guide sequences are highly effective in inducing RNase P for inhibition of gene expression and replication of human cytomegalovirus. Nucleic Acids Res (2006) 0.86
Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition. Antimicrob Agents Chemother (1992) 0.85
Synthesis of 2'-modified nucleotides and their incorporation into hammerhead ribozymes. Nucleic Acids Res (1995) 0.85
An anti-lymphocytic choriomeningitis virus ribozyme expressed in tissue culture cells diminishes viral RNA levels and leads to a reduction in infectious virus yield. J Virol (1993) 0.84
Inhibition of fatty acid synthesis by expression of an acetyl-CoA carboxylase-specific ribozyme gene. Proc Natl Acad Sci U S A (1994) 0.84
Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell (2001) 8.09
Synthesis and use of synthetic oligonucleotides. Annu Rev Biochem (1984) 4.53
Growth inhibition by acycloguanosine of herpesviruses isolated from human infections. Antimicrob Agents Chemother (1979) 3.61
A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med (1991) 3.05
Antibody to varicella-zoster virus-induced membrane antigen: immunofluorescence assay using monodisperse glutaraldehyde-fixed target cells. J Infect Dis (1977) 2.65
Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol (1994) 2.50
Psychotoxic effects of benzhexol hydrochloride (Artane). Br J Psychiatry (1967) 2.48
Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med (1983) 2.03
Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med (1983) 1.90
Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA. Proc Natl Acad Sci U S A (2000) 1.88
The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA (1997) 1.84
Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation (1997) 1.84
Is there a role for gastric accommodation and satiety in asymptomatic obese people? Obes Res (2001) 1.84
Direct detection of HIV-1 RNA from AIDS and ARC patient samples. DNA (1988) 1.79
Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1. EMBO J (1994) 1.77
Inhibition of human immunodeficiency virus by using an oligonucleoside methylphosphonate targeted to the tat-3 gene. J Virol (1988) 1.73
Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther (1997) 1.71
Unexpected point mutations activate cryptic 3' splice sites by perturbing a natural secondary structure within a yeast intron. Genes Dev (1991) 1.70
Structure and organization of the two tRNATyr gene clusters on the E. coli chromosome. Cell (1979) 1.68
Refractive adaptation in amblyopia: quantification of effect and implications for practice. Br J Ophthalmol (2004) 1.67
Homology between murine and human cellular DNA sequences and the terminal repetition of the S component of herpes simplex virus type 1 DNA. Cell (1982) 1.67
An alternate method for synthesis of double-stranded DNA segments. J Biol Chem (1982) 1.63
The first ATPase domain of the yeast 246-kDa protein is required for in vivo unwinding of the U4/U6 duplex. RNA (1999) 1.62
Specificity of the blastogenic response of human mononuclear cells to herpesvirus antigens. Infect Immun (1978) 1.60
Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? Blood (1994) 1.56
Partial purification and some properties of delta1-pyrroline-5-carboxylate reductase from Escherichia coli. J Bacteriol (1977) 1.49
Immune response to herpesvirus antigens in adults with acute cytomegaloviral mononucleosis. J Infect Dis (1979) 1.46
Differential transcription of Pgk genes during spermatogenesis in the mouse. Dev Biol (1992) 1.41
Proline excretion and indirect suppression in Escherichia coli and Salmonella typhimurium. J Bacteriol (1974) 1.41
Detection of drug resistance in human tumors by in vitro enzymatic amplification. Cancer Res (1988) 1.40
Adductor myonecrosis following prostate biopsy. Aust N Z J Surg (1997) 1.39
Airborne transmission of chickenpox in a hospital. N Engl J Med (1980) 1.39
Differential recovery of auxotrophs after penicillin enrichment in Escherichia coli. J Bacteriol (1971) 1.39
Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci U S A (1991) 1.37
Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther (2007) 1.34
Biological expression of an Escherichia coli consensus sequence promoter and some mutant derivatives. Proc Natl Acad Sci U S A (1983) 1.33
Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. Gene Ther (2008) 1.32
Design of the Monitored Occlusion Treatment of Amblyopia Study (MOTAS). Br J Ophthalmol (2002) 1.32
Cloning and physical mapping of a gene fragment coding for a 64-kilodalton major late antigen of human cytomegalovirus. Proc Natl Acad Sci U S A (1984) 1.30
RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts. Nucleic Acids Res (2000) 1.27
Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo. Gene Ther (2009) 1.27
Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection. Proc Natl Acad Sci U S A (1987) 1.26
A test for intron function in the yeast actin gene. Nature (1985) 1.24
Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo. Nucleic Acids Res (1992) 1.24
Identification and characterization of yeast mutants that overcome an experimentally introduced block to splicing at the 3' splice site. RNA (1996) 1.24
Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis (1983) 1.24
Noninvasive measurement of gastric accommodation in patients with idiopathic nonulcer dyspepsia. Am J Gastroenterol (2001) 1.23
Prolonged human cytomegalovirus viremia following bone marrow transplantation. Transplantation (1984) 1.23
Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years. Clin Exp Immunol (2011) 1.23
Yeast pre-messenger RNA splicing efficiency depends on critical spacing requirements between the branch point and 3' splice site. EMBO J (1986) 1.22
Characterization of an essential HSV-1 protein encoded by the UL25 gene reported to be involved in virus penetration and capsid assembly. Virology (1996) 1.22
Effect of cyclooxygenase-2 inhibitors on gastric emptying and small intestinal transit in humans. Neurogastroenterol Motil (2004) 1.19
Herpes simplex virus DNA in normal corneas: persistence without viral shedding from ganglia. J Med Virol (1995) 1.19
Effect of female sex hormone supplementation and withdrawal on gastrointestinal and colonic transit in postmenopausal women. Neurogastroenterol Motil (2006) 1.15
CD13 (human aminopeptidase N) mediates human cytomegalovirus infection. J Virol (1993) 1.14
Recurrent laryngeal nerve paralysis: compression by a thyroid cyst. Med J Aust (1980) 1.13
Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene (1994) 1.13
Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther (2006) 1.11
Structural organization of Escherichia coli tRNAtyr gene clusters in four different transducing bacteriophages. J Mol Biol (1979) 1.10
A prospective analysis of nosocomial wound infection after mastectomy. Arch Surg (1983) 1.09
Different sizes of restriction endonuclease fragments from the terminal repetitions of the herpes simplex virus type 1 genome latent in trigeminal ganglia of mice. J Gen Virol (1984) 1.08
Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection. Studies in a patient with non-Hodgkin lymphoma. Ann Intern Med (1989) 1.08
Isolation and partial chemical characterization of a 64,000-dalton glycoprotein of human cytomegalovirus. J Virol (1984) 1.07
Oligonucleotide probes for the detection of TEM-1 and TEM-2 beta-lactamase genes and their transposons. Can J Microbiol (1987) 1.06
Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation (1988) 1.05
Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum Gene Ther (1999) 1.04
The immediate-early enhancer element of herpes simplex virus type 1 can replace a regulatory region of the c-Ha-ras1 oncogene required for transformation. J Virol (1985) 1.03
Polypeptide-specific antibody response to human cytomegalovirus after infection in bone marrow transplant recipients. J Infect Dis (1986) 1.03
Measurement of d sigma/dM and forward-backward charge asymmetry for high-mass Drell-Yan e(+)e(-) pairs from pp macro collisions at square root of s = 1.8 TeV. Phys Rev Lett (2001) 1.02
Isolation and functional analysis of a Kluyveromyces lactis RAP1 homologue. Gene (1994) 1.02
A rapid radioimmunoassay using 125I-labeled staphylococcal protein A for antibody to varicella-zoster virus. J Infect Dis (1981) 1.01
A recombinant vaccinia virus expressing herpes simplex virus type 1 glycoprotein B induces cytotoxic T lymphocytes in mice. J Gen Virol (1988) 1.01
Seroepidemiologic studies of cytomegalovirus and Epstein-Barr virus infections in relation to human immunodeficiency virus type 1 infection in selected recipient populations. Transfusion Safety Study Group. J Acquir Immune Defic Syndr (1989) 1.00
Comparison of plasma PCR and bronchoalveolar lavage fluid culture for detection of cytomegalovirus infection in adult bone marrow transplant recipients. J Clin Microbiol (1994) 1.00
Detection of antisense and ribozyme accessible sites on native mRNAs: application to NCOA3 mRNA. Mol Ther (2001) 1.00
Human cytomegalovirus strain Towne pp65 gene: nucleotide sequence and expression in Escherichia coli. Virology (1991) 0.99
Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems. AIDS Res Hum Retroviruses (1992) 0.99
Complications from silicon-polymer intubulation of nerves. Microsurgery (1989) 0.98
Kluyveromyces lactis maintains Saccharomyces cerevisiae intron-encoded splicing signals. Mol Cell Biol (1989) 0.98
Isolation of a mouse pseudo tRNA gene encoding CCA--a possible example of reverse flow of genetic information. Nature (1982) 0.97
Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts. Nucleic Acids Res (1998) 0.97
Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts. Antisense Nucleic Acid Drug Dev (2000) 0.97
Polypeptide specificity of the early antibody response following primary and recurrent genital herpes simplex virus type 2 infections. J Gen Virol (1984) 0.95
Inhibition of HIV-1 replication with designed miRNAs expressed from RNA polymerase II promoters. Gene Ther (2007) 0.95
Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood (1993) 0.95
Measurement of the strong coupling constant from inclusive jet production at the Tevatron pp collider. Phys Rev Lett (2002) 0.94
Search for gluinos and scalar quarks in pp collisions at square root[s] = 1.8 TeV using the missing energy plus multijets signature. Phys Rev Lett (2002) 0.93
Pretransplant pulmonary function predicts cytomegalovirus-associated interstitial pneumonia following bone marrow transplantation. Chest (1992) 0.93
Current progress in the development of RNAi-based therapeutics for HIV-1. Gene Ther (2011) 0.93
Intracellular applications of ribozymes. Methods Enzymol (2001) 0.92
Infection of human peripheral blood mononuclear cells by varicella-zoster virus. Intervirology (1982) 0.92
Proline excretion in Escherichia coli: a comparison of an argD+ strain and a proline-excreting argD- derivative. Biochem Genet (1977) 0.91